GlobeNewswire

Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark

Share
  • This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer
  • PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer, with nearly 40 percent of patients harbouring a mutation in this gene1
  • The cobas PIK3CA Mutation Test is a PCR-based test that detects PIK3CA mutations in patients with metastatic breast cancer to help identify those most likely to benefit from approved therapy2

Basel, 15 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® PIK3CA Mutation Test for patients with advanced or metastatic breast cancer. Previously only available as research use only (RUO), this in vitro diagnostic (IVD) test is now available in countries accepting the CE mark.

“Nearly two million women are diagnosed with breast cancer each year, and an estimated half a million could harbour a PIK3CA mutation.3,4 If correctly identified, some of these women may benefit from targeted therapy,” said Thomas Schinecker, CEO Roche Diagnostics. “We are pleased to offer the cobas PIK3CA Mutation Test CE-IVD, enabling clinicians to accurately and quickly manage their breast cancer patients.”

In advanced or metastatic breast cancer, PIK3CA mutations are associated with tumour growth, resistance to endocrine treatment, and a poor overall prognosis. The cobas PIK3CA Mutation Test detects 17 mutations in the PIK3CA gene and can help clinicians identify patients who may benefit from phosphoinositide 3-kinase (PI3K) targeted therapy as supported by medical guidelines.5,6

About the cobas PIK3CA Mutation Test
The cobas PIK3CA Mutation Test is a real-time PCR test for the qualitative detection and identification of 17 mutations in exons 2, 5, 8, 10, and 21 in the gene encoding the catalytic subunit of PIK3CA in DNA isolated from formalin-fixed paraffin-embedded tissue (FFPET). The cobas PIK3CA Mutation Test is intended to identify patients with metastatic breast cancer whose tumours harbour these mutations.

The cobas PIK3CA Mutation Test provides automated results reporting, with flexible throughput to process up to 30 samples per run on the widely available cobas z 480 Analyzer. Specimens are processed using the cobas® DNA Sample Preparation Kit to isolate genomic DNA from FFPET human specimens. Using a standardised workflow, the cobas PIK3CA Mutation Test provides fast time-to-results in under eight hours.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Vasan N et al Annals of Onco 2019
[2] cobas® PIK3CA Mutation Test CE-IVD package insert
[3] GLOBOCAN 2018
[4] seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed on 30 Nov 2020
[5] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) https://doi.org/10.1016/j.annonc.2020.09.010
[6] 6.      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.6.2020

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction25.1.2021 14:00:00 CETPress release

PRESS RELEASE January 25, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2 million) in an upfront payment resulting from the now completed acquisition of Cadent Therapeutics by a third party. Saniona holds an ownership stake of approximately 3% in Cadent Therapeutics resulting from Cadent’s previous acquisition of the Saniona spin-out Ataxion, which was created to leverage Saniona’s ion channel expertise for the treatment of movement disorders. Saniona previously announced the planned acquisition and its ownership stake in December 2020. “Saniona has developed a robust, proprietary drug discovery engine focused on ion channels, a rare scientifically validated drug class that remains significantly untapped,” said Jørgen Drejer, Chief Scientific Officer of Saniona. “It is gratifying to see our ion channel programs create value, and the funding that Saniona received from th

Saniona har erhållit upfrontbetalning om cirka 2,9 miljoner USD (24,2 miljoner SEK) i samband med förvärvet av Cadent Therapeutics25.1.2021 14:00:00 CETPressemelding

PRESSMEDDELANDE 25 januari 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännagav idag att Saniona tillförts cirka 2,9 miljoner USD (24,2 miljoner SEK) i upfrontbetalning, till följd av det nu genomförda förvärvet av Cadent Therapeutics av en tredje part. Saniona har en ägarandel om cirka 3 % i Cadent Therapeutics efter Cadents tidigare förvärv av Sanionas avknoppning Ataxion, som bildades för att utnyttja Sanionas expertis inom jonkanaler för behandling av motoriska störningar. Saniona har tidigare, i december 2020, meddelat om det planerade förvärvet samt bolagets ägarandel. ”Saniona har utvecklat en robust, proprietär plattform för upptäckter av nya läkemedel med fokus på jonkanaler – en av ett fåtal vetenskapligt validerade läkemedelsklasser som fortfarande är i huvudsak outnyttjade”, säger Jørgen Drejer, Chief Scientific Officer på Saniona. "Det är glädjande att se att våra jonkanalsprogram skapar värde och de

DFDS A/S: DFDS udvider logistikaktiviteter i Sverige med ny lagerbygning i Borås25.1.2021 13:51:10 CETpressemeddelelse

Investor News DFDS har i dag indgået aftale om at lease en ny lagerbygning på 34.560 kvadratmeter i Borås, der er et attraktivt logistikknudepunkt for Skandinavien tæt på Gøteborg. Den nye lagerbygning udvider DFDS’ kontraktlogistikforretning, som i dag er koncentreret i Gøteborg. Den ekstra kapacitet gør det muligt at skabe vækst for eksisterende industrikunder samt tiltrække nye kunder. Lagerbygningen udvikles og opføres af udviklingsselskabet, CH Square, som DFDS leaser lagerbygningen af på en 10-årig aftale med mulighed for at forlænge aftalen efter leasingperioden. Byggeriet forventes at gå i gang i begyndelsen af februar 2021, og lagerbygningen forventes at åbne ved årets udgang. Der er ikke væsentlige investeringer knyttet til den nye lagerbygning. Den investerede kapital forventes at blive omkring DKK 80 mio. efter kapitalisering af leasingkontrakten i henhold til IFRS 16. Kontakt Torben Carlsen, CEO +45 33 42 32 01 Karina Deacon, CFO +45 33 42 33 42 Søren Brøndholt Nielsen, IR

DFDS A/S: DFDS expands logistics offering in Sweden with new warehouse in Borås25.1.2021 13:51:10 CETPress release

Investor news DFDS has today entered into an agreement to lease a new 34,560 sqm warehouse in Borås, Sweden, that is an attractive Scandinavian logistics hub area close to Gothenburg. The new warehouse will expand DFDS’ contract logistics offering that today is focused in Gothenburg. The additional capacity will make it possible to grow with existing industrial customers and attract new customers. The warehouse will be built by property developer, CH Square, from whom DFDS will lease the warehouse for 10 years with an option to extend further after the lease period. Construction is expected to begin in early February 2021 and the warehouse is planned to open at the end of this year. There are no material investments related to the new warehouse. The invested capital of the warehouse is expected to be around DKK 80m following capitalisation of the lease contract according to IFRS 16. Contact Torben Carlsen, CEO +45 33 42 32 01 Karina Deacon, CFO +45 33 42 33 42 Søren Brøndholt Nielsen,

Talenom Plc will publish its Financial Statements Bulletin for 2020 on 8 February 2021 at 13:30 EET25.1.2021 11:00:00 CETPress release

Talenom Plc, Press release 25 January 2021 at 12:00 EET Talenom Plc will publish its Financial Statements Bulletin for 2020 on 8 February 2021 at 13:30 EET Talenom Plc will publish its Financial Statements Bulletin for 2020 on Monday 8 February 2021 at 13:30 EET. The company’s CEO Otto-Pekka Huhtala will present the highlights of the release for analysts, investors and media in Finnish, followed by CFO Antti Aho’s presentation in English as a live webcast on Monday 8 February 2021 at 14:00 EET. The webcast can be viewed online at https://talenom.videosync.fi/tilinpaatos-2020. Participants will have the opportunity to present questions during the briefing over the webcast platform. The presentation materials will be published before the start of the briefing on the company’s website at Talenom.fi/en/investors. TALENOM PLC Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 8554 otto-pekka.huhtala@talenom.fi Talenom is an agile and progressive accounting firm established